Infliximab reduces myeloperoxidase concentration in chronic inflammatory joint diseases

Montserrat Feijóo, Isaac Túnez, Inmaculada Tasset, Pedro Montilla, Verónica Pérez-Guijo, Elisa Muñoz-Gomariz, Adela Ruiz, Ruxandra Schiotis, Eduardo Collantes

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


The present study evaluated the effect of infliximab on the myeloperoxidase (MPO) concentration in chronic inflammatory joint disease. Eighteen patients were divided into active and inactive groups. Erythrocyte sedimentation rate, C-reactive protein, white blood cell counts, MPO concentration, and biomarkers of oxidative stress were measured before and after the infusion of infliximab. Patients with active disease showed increases in concentrations of MPO and biomarkers of oxidation, but decreases in antioxidant parameters. After infliximab treatment, both inflammatory parameters and MPO concentrations were normalized. In conclusion: (1) the MPO concentration is related to inflammatory activity and could play an important role in the maintenance and outbreak of oxidative stress present in these diseases, and (2) infliximab inhibits MPO concentration.

Original languageEnglish (US)
Pages (from-to)211-216
Number of pages6
Issue number4
StatePublished - Apr 1 2009
Externally publishedYes


  • Ankylosing spondylitis
  • Chronic inflammatory joint disease
  • Infliximab
  • Myeloperoxidase
  • Oxidative stress
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Pharmacology


Dive into the research topics of 'Infliximab reduces myeloperoxidase concentration in chronic inflammatory joint diseases'. Together they form a unique fingerprint.

Cite this